Welcome to our dedicated page for Charlottes Web news (Ticker: CWBHF), a resource for investors and traders seeking the latest updates and insights on Charlottes Web stock.
Charlotte's Web Holdings, Inc. reports developments around its hemp-derived botanical wellness business, including operating results, cost structure updates, product-channel activity, and federal policy affecting CBD and full-spectrum hemp products. The company describes itself as a Certified B Corporation focused on hemp extract wellness, with categories that include CBD tinctures, gummies, capsules, topical creams and lotions, hemp-derived THC microdose gummies, functional mushroom gummies, and CBD pet products.
Recurring updates also cover regulatory and healthcare-access initiatives for eligible hemp products, distribution through retailers, healthcare practitioners, and online channels, and its exposure to cannabinoid pharmaceutical development through DeFloria. News frequently links these themes to product quality controls, vertically integrated operations, shareholder matters, and capital-structure or governance developments.
Charlotte's Web (OTC: CWBHF) praised Representative Morgan Griffith for leading the introduction of the HEMP Act, a federal hemp bill described as establishing FDA oversight, manufacturing standards, and consumer safety requirements while preserving lawful access to compliant CBD products. The company said the framework aims to target unsafe and illicit products while protecting responsible, lawfully sold hemp-derived cannabinoids used by patients, veterans, and other consumers.
Charlotte's Web also thanked patient advocates and Coalition for Access Now for uniting stakeholders behind a science-based hemp marketplace.
DeFloria (OTCQB:CWBHF) says a Presidential Executive Order reclassifying cannabis to Schedule III accelerates its FDA botanical drug program for autism-related irritability. DeFloria reports a cleared botanical IND, a Study May Proceed letter, a completed Phase 1 PK/PD trial showing safety and tolerability, and FDA authorization to start a Phase 2 program for AJA001 oral solution. The company positions these milestones and standardized pharmaceutical-grade formulation as catalysts for research funding, academic trials, institutional investment, and pharma partnerships after rescheduling on Dec 19, 2025.
Charlotte's Web (OTCQB: CWBHF) will serve as a CBD provider in a landmark CMMI Medicare and Medicaid pilot announced Dec 18, 2025, enabling reimbursement for science-backed CBD for senior oncology patients.
The company plans to offer selected products early 2026 via a secure online healthcare portal that combines eCommerce with advanced data security. The pilot pairs Realm of Caring for patient support and the company's Scientific Advisory Board for clinical guidance, and targets improved affordability for seniors within a population of 67 million Medicare beneficiaries.
ONE HEMP (CWBHF) warns that language in the Agriculture, Rural Development, and FDA Appropriations Act would effectively ban many full-spectrum CBD products by imposing a 0.4 mg total THC per container limit, which the group calls unscientific and harmful to consumer access. ONE HEMP cites peer-reviewed research (Dr. Ryan Vandrey) and industry experts (Dr. Marcel Bonn-Miller) to argue that oral THC up to 2.8 mg shows no subjective impairment and that trace THC supports a full-spectrum "entourage effect."
The bill includes a one-year implementation window; House and Senate lawmakers are preparing parallel legislative responses to establish manufacturing, labeling, synthetic cannabinoid prohibitions, and youth safeguards. ONE HEMP is mobilizing stakeholders to seek balanced, science-based regulation that preserves consumer access and public health.
Charlotte's Web (OTC:CWBHF) reported Q3 2025 results on Nov 12, 2025: consolidated revenue of $11.5M (down 8.6% YoY), gross profit of $4.5M (38.9% margin), and net loss of $5.8M or $(0.04) per share. Adjusted EBITDA improved to $(2.1)M from $(3.9)M a year ago.
Operational highlights include full internalization of Brightside gummy manufacturing, a Scientific Advisory Board launch, a B2B channel restructuring with a $0.5M chargeback reserve, and FDA clearance for DeFloria Phase 2 IND for ASD irritability. Cash was $9.8M and total assets $81.6M as of Sept 30, 2025.
Charlotte's Web (OTCQB: CWBHF) announced the appointment of M. Borgia Walker to its Board of Directors, effective November 1, 2025. Walker brings ~30 years of leadership in transformation, finance, audit, compliance, HR and M&A from global consumer goods and financial services.
She currently serves as Chief People Officer at Reynolds American, led a multi-year transformation as VP of Strategic Projects (2017–2023), is a CPA, and holds a BS in Accountancy plus an MBA in Finance. Walker replaces Jonathan Atwood and increases the board to six directors.
Charlotte's Web (OTCQB:CWBHF) launched Knockout, a blackberry-flavored hemp-derived THC + CBN sleep gummy, on October 14, 2025. Each 20-count bottle retails for $39.99 and is sold online and at select retailers nationwide.
Knockout uses the AZUCA TiME INFUSION™ delivery system for rapid onset (5–15 minutes), pairs THC to aid sleep onset with CBN to support uninterrupted rest, and is vegan, gluten-free, and made with U.S.-grown hemp.
Charlotte's Web (OTCQB: CWBHF) has launched Quiet Sleep Mushroom Gummies, expanding its sleep category with a melatonin-free and CBD-free sleep support solution. The new product combines organic reishi mushroom, chamomile flower extract, and magnesium citrate to promote relaxation and quality sleep.
The launch addresses a significant market need, as 43% of Americans report difficulty falling asleep due to racing minds. Available in strawberry lemon flavor, the gummies are priced at $34.99 for a 60-count bottle and will be available through the company's website starting September 30, 2025.
Charlotte's Web (OTCQB: CWBHF), a pioneer in hemp-derived CBD wellness, has announced plans to establish a Scientific Advisory Board in September 2025 to strengthen its medical channel strategy and accelerate R&D initiatives. The board will be led by Dr. Marcel Bonn-Miller, Chief Scientific Officer, a renowned cannabinoid researcher with over 20 years of experience.
The initiative aims to guide research and development, shape clinical initiatives, and create Continuing Medical Education (CME) content for healthcare professionals. This development reinforces the company's partnership with DeFloria, Inc. and Ajna BioSciences PBC, particularly in advancing AJA001, their FDA-approved Phase 2 clinical trial candidate for treating irritability associated with autism spectrum disorder.
Charlotte's Web (OTC:CWBHF) reported its Q2 2025 financial results, marking its second consecutive quarter of year-over-year growth. Revenue increased 4.2% to $12.8 million, while net loss improved to $6.3 million ($0.04 per share) from $11.0 million in Q2 2024.
The company achieved significant cost reductions, with SG&A expenses decreasing 31.7% year-over-year. Gross profit improved to $6.0 million (46.8% margin). Key operational highlights include the successful launch of Brightside™ THC gummies, expansion of botanical wellness portfolio, and implementation of in-house gummy production expected to generate $3 million in annualized cost savings.
Post-quarter initiatives are projected to reduce annualized costs by an additional $6 million in 2026. The company maintains a strong financial position with $15.3 million in cash and continues progress in FDA-cleared Phase 2 clinical trials for ASD treatment.